Skip to content

A randomized controlled study of ReGeneraTing Agents(RGTA ®) in the treatment of jaw cysts

A randomized controlled study of ReGeneraTing Agents(RGTA ®) in the treatment of jaw cysts

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093663
Enrollment
Unknown
Registered
2024-12-10
Start date
2024-12-10
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

jaw cysts

Interventions

Sponsors

School and Hospital of Stomatology, China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis of jaw cyst was made on CBCT and postoperative pathology, the diameter of the cyst was 1.5-4.5 cm, and there was no secondary infection of the jaw cyst. 2. age >=18 years. 3. Before operation, complete root canal treatment was performed for lesions affected by cysts, and tooth extraction was performed for lesions that could not be retained such as degree III loosening. 4. Smoking less than 10 cigarettes a day, no alcoholism. 5. Patients whose systemic systemic examination and laboratory tests did not show obvious systemic diseases and contraindications to surgery. 6. Patients were informed of the content of this study and signed informed consent. 7. Patient compliance is good, can cooperate with treatment, regular review.

Exclusion criteria

Exclusion criteria: 1. Patients with severe liver and kidney dysfunction or coagulation dysfunction. 2. The cyst was recurrent. 3. Patients with acute infection or osteomyelitis. 4. Patients with osteoporosis, diabetes, malignant tumors and other systemic diseases that affect bone healing or bone regeneration. 5. Patients with more serious periodontal disease, unable to maintain oral hygiene. 6. Patients who do not qualify for curettage of jaw cyst, or have serious segmental defects after jaw cyst removal, and must undergo autologous bone transplantation and strong internal fixation with titanium plates. 7. Those with pathological diagnosis of malignant tumour. 8. Patients with a history of bisphosphonates and a history of radiotherapy and chemotherapy within six months. 9. Patients are pregnant or breastfeeding. 10. Patients with poor compliance, unable to cooperate with treatment and follow-up work, clinical and follow-up data is incomplete.

Design outcomes

Primary

MeasureTime frame
Evaluation of osteogenic effect;

Secondary

MeasureTime frame
The number of teeth lost and the number of teeth recovered after operation;Degree of swelling;Keratinized gum width;

Countries

China

Contacts

Public ContactFayu Liu

School and Hospital of Stomatology, China Medical University

lfyhjk@126.com+86 180 4022 9113

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026